Is Johnson & Johnson Stock Worth Buying on the Dip?

Is Johnson & Johnson Stock Worth Buying on the Dip?

The news hasn't been great lately for healthcare giant Johnson & Johnson (NYSE: JNJ). On Jan. 24, the company reported fourth-quarter revenue of $23.7 billion, down 4.4% year over year, and earnings per share (EPS) of $1.33, down 24.9% over the previous year's quarter. Then, on Jan. 30, the Third Circuit Court of Appeals rejected the company's use of Chapter 11 bankruptcy in a shell company known as LTL Management, to avoid lawsuits over whether its talc products caused cancer.